
==== Front
Biomedicines
Biomedicines
biomedicines
Biomedicines
2227-9059
MDPI

10.3390/biomedicines12020464
biomedicines-12-00464
Article
Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells
https://orcid.org/0009-0007-4967-2499
Ipavec Nina Conceptualization Methodology Formal analysis Investigation Writing – original draft Writing – review & editing 1
https://orcid.org/0000-0001-8516-9718
Rogić Vidaković Maja Conceptualization Writing – original draft Writing – review & editing Supervision 2*
https://orcid.org/0000-0002-6118-6975
Markotić Anita Methodology Writing – review & editing Supervision 3
Pavelin Sanda Conceptualization Methodology Investigation Resources 4
Buljubašić Šoda Maja Methodology Investigation Writing – original draft Writing – review & editing 5
https://orcid.org/0000-0002-5825-8026
Šoda Joško Software Writing – review & editing Visualization 6
https://orcid.org/0000-0003-0018-0075
Dolić Krešimir Investigation Resources Data curation 78
https://orcid.org/0000-0002-9628-1067
Režić Mužinić Nikolina Methodology Software Validation Formal analysis Investigation Writing – original draft 3*
Rivera Víctor M. Academic Editor
Cavalcante Paola Academic Editor
Andreetta Francesca Academic Editor
1 Transfusion Medicine Division, University Hospital of Split, 21000 Split, Croatia; nina.ipavec@gmail.com
2 Laboratory for Human and Experimental Neurophysiology, Department of Neuroscience, School of Medicine, University of Split, 21000 Split, Croatia
3 Department of Medical Chemistry and Biochemistry, School of Medicine, University of Split, 21000 Split, Croatia
4 Department of Neurology, University Hospital of Split, 21000 Split, Croatia
5 Department of Pediatrics, University Hospital of Split, 21000 Split, Croatia
6 Signal Processing, Analysis, Advanced Diagnostics Research and Education Laboratory (SPAADREL), Department for Marine Electrical Engineering and Information Technologies, Faculty of Maritime Studies, University of Split, 21000 Split, Croatia
7 Department of Interventional and Diagnostic Radiology, University Hospital of Split, 21000 Split, Croatia
8 Department of Radiology, School of Medicine, University of Split, 21000 Split, Croatia
* Correspondence: maja.rogic@mefst.hr (M.R.V.); nikolina.rezic@mefst.hr (N.R.M.)
19 2 2024
2 2024
12 2 46407 12 2023
05 2 2024
16 2 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
The objective of this study was to investigate regulatory T cells (Tregs) and monocytes; specifically, the expression of CTLA-4 (CD152) and FOXP3+ in CD4+CD25+ Tregs and the expression of CD40+ and CD192+ monocyte subpopulations in subjects with primary progressive multiple sclerosis (PPMS). Immunological analysis was conducted on peripheral blood samples collected from the 28 PPMS subjects (15 treated with ocrelizumab and 13 untreated PPMS subjects) and 10 healthy control subjects (HCs). The blood samples were incubated with antihuman CD14, CD16, CD40, and CD192 antibodies for monocytes and antihuman CD4, CD25, FOXP3, and CTLA-4 antibodies for lymphocytes. The study results showed that in comparison to HCs both ocrelizumab treated (N = 15) and untreated (N = 13) PPMS subjects had significantly increased percentages of CTLA-4+ and FOXP3+ in CD4+CD25+ Tregs. Further, ocrelizumab treated PPMS subjects, compared to the untreated ones, had significantly decreased percentages of CD192+ and CD40+ nonclassical monocytes. Increased percentages of CTLA-4+ and FOXP3+ in CD4+CD25+ Tregs in both ocrelizumab treated and untreated PPMS subjects indicates the suppressive (inhibitory) role of Tregs in abnormal immune responses in PPMS subjects. Decreased percentages of CD40+, CD192+, and CD14+CD16++ monocytes for treated compared to untreated PPMS subjects suggests a possible role for ocrelizumab in dampening CNS inflammation.

PPMS
regulatory T cells (Tregs)
lymphocytes
Forkhead box protein P3
CTLA-4
monocyte subpopulations
ocrelizumab
Investigation of subclinical markers of multiple sclerosisThis research was funded by the research funding for science program for universities in the Republic of Croatia with the University of Split, Croatia (N. Režić Mužinić; (N.R.M.), A. Markotić (A.M.), S. Pavelin (S.P.)) and Croatian Science Foundation (IP-2022-10-6203): Project titled: “Investigation of subclinical markers of multiple sclerosis”, project acronym: SUBCLIN-MS (Principal Investigator: Maja Rogić Vidaković, M.R.V.).
==== Body
pmc1. Introduction

Multiple sclerosis (MS) is a disease characterized by multifocal demyelination leading to progressive neurodegeneration. It is caused by an autoimmune response directed against self-antigens within the central nervous system [1]. MS predominantly affects female subjects, with symptoms often starting to present in early adulthood. MS can be classified into two primary forms: the more common relapsing–remitting MS (RRMS), which is seen in about 85–90% of cases, and primary progressive MS (PPMS) [2]. RRMS exhibits cycles of neurological setbacks (relapses) followed by remission phases. However, eventually, most RRMS cases evolve into the consistently deteriorating condition known as secondary progressive MS (SPMS). On the other hand, the rarer form, PPMS, accounting for about 10–20% of MS diagnoses, presents as a persistent decline in neurological function from its onset, without periods of remission [3]. The fundamental pathological occurrence in MS is demyelination, accompanied by axonal degeneration and loss, leading to permanent functional impairments [4,5,6]. From an immunological perspective, MS arises due to aberrant immune system activation. Autoreactive CD4+ T cells bypass both negative selection and clonal elimination and penetrate the compromised blood–brain barrier to access the CNS and initiate the attraction of other inflammatory agents, including microglia, macrophages, and B cells. This cascade promotes antibody production and the release of proinflammatory cytokines, ultimately damaging the myelin sheath [7,8,9]. It is well established that autoreactive T cells play an important role in MS, as well as in other conditions such as psoriasis, diabetes mellitus type 1, oral lichen planus, myasthenia gravis, etc. [8,10,11,12,13]. Regulatory T cells (Tregs), a specific subset of T cells, are functionally changed in different autoimmune diseases [14,15,16,17,18,19,20], including MS [21,22,23,24,25,26]. Treg cells are distinguished as a CD4+ T cell subset that express the interleukin-2 receptor alpha chain CD25 and the pivotal transcription factor Forkhead box protein P3 (FOXP3). The presence of FOXP3 is vital for Treg cell development, functionality, and stability [27,28,29,30]. Also, Tregs markedly express the immune checkpoint receptor cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), also known as CD152. A deficiency in Treg-associated CTLA-4 can result in severe systemic autoimmune reactions [31,32]. Treg cells inhibit the activity of numerous cell types, including cytotoxic CD8+ T cells (Teffs) and antigen-presenting cells (APC). Tregs employ a variety of mechanisms to achieve inhibition of various cells (Teffs, APCs, etc.) ranging from direct cell-to-cell interactions to the release of suppressive cytokines [33].

Besides the role of autoreactive T cells in MS, monocytes and macrophages also contribute to proinflammatory and anti-inflammatory responses [34,35]. Monocytes are classified into three distinct subpopulations: classical (CD14++CD16−), intermediate (CD14++CD16+), and nonclassical (CD14+CD16++). Gjelstrup et al. [36] reported an increase in nonclassical monocytes, accompanied by a notable decrease in classical monocytes, as well as variations in the expression of CD40 and CD192, among MS subjects when compared to controls.

There are different treatment approaches for MS depending on the patient’s clinical symptoms. They may include treatment of relapse symptoms with steroid drugs and reducing the number of relapses with disease-modifying drugs (DMD) [37]. Ocrelizumab stands out as the sole approved DMD for PPMS. It reduces the progression of clinical impairment by around 25% and improves both clinical and magnetic resonance imaging (MRI) indicators of inflammation and degeneration in PPMS [38].

The present study aimed to investigate the expression of CTLA-4+ and FOXP3+ in CD4+CD25+ in Tregs, and CD40 and CD192 in the classical (CD14++CD16−), intermediate (CD14++CD16+), and nonclassical (CD14+CD16++) monocyte subsets in PPMS (ocrelizumab treated and untreated) subjects.

2. Materials and Methods

2.1. Participants

The study sample included twenty-eight PPMS subjects recruited from the University Hospital of Split, Croatia, who met the inclusion criteria and agreed to participate in the study. The healthy control group (HCs) comprised ten subjects. Fifteen out of twenty-eight PPMS subjects were treated with ocrelizumab (Ocrevus, Roche, Grenzach-Wyhlen, Germany) for ≥12 months. The ocrelizumab dosage of 600 mg was administered per month. Thirteen PPMS subjects refused the treatment (untreated PPMS). The mean age of the PPMS subjects was 54.57 ± 8.71, and for HCs the mean age was 37 ± 13.9. The mean age of the PPMS subjects was significantly higher (p < 0.003) compared to HCs. Most PPMS subjects were women (75%). The mean disease duration was 10.74 ± 7.57 years and the median Expanded Disability Status Scale (EDSS) score was 4.94. The duration of the MS disease was significantly longer in untreated PPMS subjects (p < 0.01) compared to ocrelizumab treated PPMS subjects. No significant differences were evident in EDSS scores between ocrelizumab treated and untreated PPMS subjects. Table 1 presents the basic demographic and disease related characteristics of PPMS subjects and HCs submitted to the immunological analysis.

2.2. Data Collection Procedures: Peripheral Blood (PB) Collection, Flow Cytometry, and Clinical Assessment (Neurological)

PB was collected, followed by a neurological examination on the same day. Collection of PB and neurological examination was performed at the Department of Neurology, University Hospital of Split. Functional disability assessments of PPMS subjects were evaluated by an experienced neurologist who applied the EDSS. PB analyses were conducted at the Department of Medical Chemistry and Biochemistry, University of Split, School of Medicine.

2.3. Flow Cytometry

Blood samples for flow cytometry analysis were collected from the antecubital veins of PPMS subjects after they signed an informed consent form. In the first test tube, one hundred microliters of whole blood were incubated for 20 min in a dark environment at 25 °C using the following mixture of antibodies: 4 µL of phycoerythrin-conjugated antibodies targeting human CD16 (BD Pharmingen, San Diego, CA, USA); 4 µL of FITC-conjugated antihuman-CD14 antibodies (from BD Pharmingen, San Diego, CA, USA); 3 µL of BB700-conjugated mouse antibodies specific to human CD192 (provided by BD Horizon, San Diego, CA, USA); and 5 µL of Alexa Fluor 647-conjugated antibodies against human CD40 (sourced from BD Pharmingen). In the second test tube, one hundred microliters of whole blood were incubated with 20 µL of phycoerythrin-conjugated antibodies reactive to human CD152 (CTLA-4) (BD Pharmingen, San Diego, CA, USA); 20 µL of antihuman-CD25 FITC antibodies (BD Pharmingen, San Diego, CA, USA); 5 µL of mouse antibodies reactive to human FOXP3 conjugated with BB700 (BD Horizon, San Diego, CA, USA); and 5 µL of Alexa Fluor 647 antibodies reactive to human CD4 (BD Pharmingen, San Diego, CA, USA). Following red blood cell lysis with BD Pharm LyseTM solution (BD Biosciences, San Diego, CA, USA), flow cytometric analyses were performed using a BD Accuri C6 (BD Biosciences, Aalst, Belgium). Unstained cell samples, together with samples stained with only one antibody, were measured and processed as negative controls to set the appropriate regions. Cell acquisition was halted at 106 cells. The flow cytometry data for each marker was collected in one flow run.

Data acquired by cytometer were analysed using FlowLogic Software version 8 (Inivai Technologies, Melbourne, Australia). Monocytes (from the first test tube) and lymphocytes (from the second test tube) were recognized in the forward scatter/side scatter (FSC/SSC) dot plots. The FSC parameter indicates cell diameter, while SSC indicates cell granularity.

2.4. Statistical Analysis

For continuous parametric variables, the data were expressed as mean ± standard deviation. For continuous nonparametric variables, the median (interquartile range) was used. Categorical variables were presented as whole numbers and percentages. Student’s t-test was applied to analyze differences in continuous parametric variables, while the chi-squared test was used to compare categorical variables across different groups. Groups were compared by one-way ANOVA. Correlation analyses were conducted using the Spearman rank-order correlation coefficient (ρ).

All statistical analyses were performed using Past software (version 3.14, University of Oslo, Oslo, Norway) with the significance set at p < 0.05.

3. Results

3.1. Flow Cytometry Results on Lymphocytes of PPMS and HC Subjects

All PPMS subjects’ findings differed from the HCs in the percentage of CD4+CD25+high, CD4+CD25+, and surface expression of CD4+CD25+highFOXP3+ and CD4+CD25+FOXP3+ (Table 2). Figure 1 presents median fluorescence intensity (MFI) increased surface expression of CD4+CD25+highFOXP3+ (A) and CD4+CD25+FOXP3+ (B) in PPMS subjects (treated and untreated), compared to the HCs. Untreated PPMS subjects had significantly increased percentages of CD4+CD25+high (p < 0.01), as well as significantly increased percentages of CD4+CD25+ (p = 0.05). All PPMS subjects’ findings differed from the HCs in their percentages of CD4+CD25+highFOXP3+ and CD4+CD25+FOXP3+. Untreated PPMS subjects had significantly increased percentages of CD4+CD25+highFOXP3+ (p < 0.05), as well as significantly increased percentages of CD4+CD25+FOXP3+ (p < 0.001). Treated PPMS subjects had significantly increased percentages of CD4+CD25+FOXP3+ (p < 0.01) but had no significantly increased percentages of CD4+CD25+highFOXP3+ when compared to HCs (Table 2).

Treated PPMS subjects had significantly increased surface expression of CTLA-4+ in CD4+CD25- (p < 0.05) compared to HCs (Table 3). Untreated PPMS subjects had significantly increased percentages of CD4+CD25-CTLA-4+ (p < 0.05) compared to HCs. All PPMS subjects’ findings differed from the HCs in the percentages of CD4+CD25+, FOXP3+, and CTLA-4+ (p < 0.005) (Table 3). Treated PPMS subjects had significantly increased percentages of CD4+CD25+, FOXP3+, and CTLA-4+ (p < 0.004) compared with untreated PPMS subjects (p < 0.01) (Table 3).

3.2. Flow Cytometry Results for Monocytes of PPMS and HC Subjects

All PPMS subjects’ findings differed from the HCs in the surface expression of CD192 in classical CD14++CD16− monocytes, the percentages of CD14++CD16+ monocytes, and the percentages of CD40+ and CD192+ in nonclassical CD14+CD16++ monocytes differed between treated and untreated PPMS subjects (Table 4). All PPMS, treated and untreated, had significantly increased surface expression of CD192 in classical monocytes (both p < 0.001).

Monocyte subpopulations are shown in Figure 2. The cell population expressions of CD14 and CD16 were displayed in a plot to identify CD14++CD16−, CD14++CD16+, and CD14+CD16++ monocyte subsets. The gated subpopulation was analyzed for its percentage and surface receptor expression of CD40 and CD192.

Figure 3 shows total monocyte control plots to monitor instrument setup and analysis strategy.

Further, treated PPMS subjects in comparison with untreated PPMS subjects also had significantly decreased percentages of CD192 and CD40 in nonclassical monocytes (p < 0.05; and p < 0.01) (Figure 4).

4. Discussion

This study investigated the expression of CTLA-4 and FOXP3 in CD4+CD25+ Treg cells, and CD40 and CD192 in monocyte subpopulations in PPMS (ocrelizumab treated and untreated) subjects compared to healthy controls. The results showed significantly increased percentages of CTLA-4 and FOXP3 in CD4+CD25+ lymphocytes for PPMS subjects, both treated and untreated, significantly increased percentages of CD4+CD25+highFOXP3+ in untreated PPMS subjects and CD4+CD25+FOXP3+ in all PPMS subjects, and significantly decreased percentages of CD192+ and CD40+ nonclassical monocytes in treated PPMS subjects.

4.1. Discussion Related to Lymphocytes Results in PPMS and HC Subjects

Tregs are CD4+ regulatory cells, which were discovered to be a unique population that inhibits the function of inflammatory cells. CD4+ Treg cells express several surface markers, including CD25, CD127 (negative-low), and FOXP3 [39]. CD25 is an IL-2 receptor α chain and is expressed abundantly on Tregs [30]. FOXP3, recognized as a master transcriptional regulator, is integral to the function and identity of regulatory T cells (Tregs). Its persistent expression is crucial for the maintenance of the suppressive functionality of mature, differentiated Treg cells. The expression of FOXP3 ensures that Tregs can effectively modulate immune responses, preventing autoimmune diseases and maintaining immune system homeostasis [40]. The mutation of FOXP3 in Tregs can induce a shift towards an autoimmune disease in both mice and humans [41,42]. The expression and mutation of FOXP3 highlight its pivotal role in maintaining the regulatory and suppressive characteristics of Tregs. Its absence can lead to the loss of these properties, resulting in the adoption of proinflammatory functions by these cells.

In the present study, all PPMS subjects, treated and untreated, showed an increase in FOXP3 expression on CD4+CD25high and also CD4+CD25+ Tregs compared with HCs, without significant differences between treated and untreated PPMS subjects. Treated PPMS subjects had slightly higher expression of FOXP3 on CD4+CD25+ compared to untreated ones. Li, Y.F. et al. [43] have performed a meta-analysis which included 16 studies, five of which identified Tregs as CD4+, CD 25+, and FOXP3+ cells. The studies in the review dated from the years 2009 to 2013. Pooling the data from these five studies showed that the proportion of Tregs in the MS patients appeared to be lower than in the controls. This meta-analysis had several limitations, such as the inclusion of various clinical subtypes of MS patients and different treatments of MS patients across the studies. These treatments may have had an influence on the proportion of Tregs in MS patients, and it is difficult to remove that influence from the results. The authors also stated that further studies are needed with independent cohorts of patients and larger sample sizes to validate their results, and that Tregs should be defined as CD4-positive, CD25-positive, and FOXP3-positive. The results from the present study also show differences in the percentages of Tregs. All PPMS subjects had significantly increased percentages of CD4+CD25+FOXP3+, while only untreated PPMS subjects had significantly increased percentages of CD4+CD25high+FOXP3+. Gonzales-Oria et al. [44] also found that percentages of Tregs (CD4+CD25highFOXP3+) were significantly higher in MS subjects (those with RRMS, PPMS, and CIS-clinical isolated syndrome). On the other hand, Kouchaki et al. [45] found a significantly lower frequency of CD4+CD25+FOXP3+ Tregs in MS subjects (with RRMS, PPMS, SPMS, CIS, and PRMS-progressive relapsing multiple sclerosis,) than in HCs, with the frequency of Tregs significantly higher in severe forms of MS (PPMS, SPMS, and PRMS) compared to the mild forms (CIS and RRMS) [44]. Ocrelizumab did not increase the percentage of CD4 Tregs over time, but markedly elevated the percentages of CD8 Tregs [46]. Chi et al. [20] documented the dysfunction of Tregs CD4+CD25highCD127lowFOXP3+ cells, which play a key role in maintaining self-tolerance.

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a surface molecule of activated T cells that maintains the homeostasis of the immune system. It modulates immune responses by competitively binding to CD80 and CD86, obstructing CD28 interaction, which raises T cell activation thresholds, markedly diminishing immune activity [47]. CTLA-4 is expressed in Tregs but can also be upregulated in other T cell subsets, notably CD4+ T cells, following activation [48]. Exhausted T cells often express CTLA-4, among various inhibitory receptors. Exhausted T-cell responses are observed in various infections, including hepatitis B and C viruses, adenovirus, lymphocytic choriomeningitis virus, leukemia virus, polyoma virus, and Friend leukemia virus. Exhausted T-cell phenomenon is also noted in patients with malignancies [49]. In our study, all PPMS subjects showed an increased percentage of CD4+CD25+ FOXP3+ (Treg) CTLA-4+ compared to HCs. Treated PPMS subjects had more significant increases in the percentages of CD4+CD25+ FOXP3+ (Treg) CTLA-4+, compared to untreated PPMS subjects. There were no significant differences in the surface expression of CTLA-4 in CD4+CD25+FOXP3+ between all PPMS groups and HCs. However, our results differ from those of Sellebjerg et al. [50], who found lower percentages of CD4+CD25high cells that were CTLA-4 positive in untreated RRMS patients and increased percentages of the same cells after IFN- β treatment. There was no correlation with the EDSS for lymphocytes and monocyte populations in PPMS subjects (treated and untreated) in the present study. Nevertheless, our finding of a more significant increase in the percentage of Treg CTLA-4+ cells in ocrelizumab treated PPMS subjects compared to untreated PPMS subjects corresponds to a slight EDSS decrease (6%) in ocrelizumab treated PPMS subjects. This suggests that CTLA-4, expressed on Treg cells, engages in trogocytosis to remove CD80/CD86 molecules from antigen-presenting cells, subsequently increasing the availability of programmed death ligand 1(PD-L1) on these cells. This process effectively reduces the presence of CD80/CD86, while enhancing free PD-L1 on the surface of antigen-presenting cells [32]. PD-L1, a molecule that plays a key role in autoantigen tolerance, can contribute to the suppression of abnormal immune responses in multiple sclerosis [51].

Untreated PPMS subjects showed increased percentages of CD4+CD25-CTLA-4+ and treated PPMS subjects showed increased expression of CTLA-4 on CD4+CD25- cells. This could indicate the activity of CD4+ activated cells due to an attempt to regulate autoimmune responses, because CTLA-4, regardless of the cell type it is expressed on, downregulates CD80 and/or CD86 on APCs by binding to and removing these molecules, thereby inhibiting T cell activation and differentiation [52]. It could also be due to the exhaustion of T cells due to chronic disease [49]. Previous studies have reported contradictory results regarding the expression of CTLA-4 in MS patients compared with HCs. While some have reported that the expression of CTLA-4 is decreased in MS patients compared with HCs [53,54,55], others have found no significant difference [56,57,58], while Kosmaczewska et al. [59] reported an increased median percentage of freshly isolated peripheral blood CD4+ CTLA-4+ T cells in MS patients. The reason for these discrepancies could be that these studies [53,54,55,56,57,58,59] were mostly performed on various different forms of MS patients (RRMS, SPMS, PPMS, CIS, etc.), while none focused solely on PPMS subjects.

4.2. Discussion Related to Monocyte Results in PPMS and HC Subjects

Monocytes are often divided into subpopulations (nonclassical CD14+CD16++, intermediate CD14++CD16+, and classical CD14++CD16−) depending on the expression of CD14 and CD16 [60]. Steinbach et al. [61] suggest that circulating monocytes and neutrophils produce inflammatory cytokines, leading to axonal damage [62]. It has been shown that the same cells, or certain subsets of classical monocytes and neutrophils, can actually oppose the initial activation and subsequent increase in pathogenic T cells [63]. CD16+ monocytes are described as being superior at activating T cells, suggesting that they are more active inducers of inflammation than the CD14+ monocytes [64] and that they can migrate through the blood–brain barrier more effectively than lymphocytes and CD14+ [65]. The findings of Waschbisch et al. [35] support the idea of the important role of CD16+ monocytes in shifting to sites of inflammation in the steady-state immune surveillance of the CNS, and they suggest that CD16+ monocytes cause the breakdown of the blood–brain barrier in CNS autoimmune diseases. Haschka et al. [66] reported that nonclassical monocyte proportions were elevated in RRMS subjects treated with natalizumab and suggested that myeloid cell immunophenotyping in MS may help to identify inactive RRMS earlier and facilitate monitoring of DMT response. Previous research in patients with systemic lupus and sepsis demonstrated that nonclassical monocytes have an inflammatory phenotype upon activation by high levels of proinflammatory cytokines and low levels of anti-inflammatory IL-10 [67]. The results from the present study show a significantly decreased percentage of CD40+, CD192+, and CD14+CD16++ monocytes for treated PPMS compared to untreated PPMS. Monocyte CD192 expression enables it to cross the blood–CNS barrier [68]. Further, monocyte CD40 binding to soluble CD40 ligands (CD40L) converts it to an antigen-presenting cell, which leads to T and B cell activation and CNS inflammation [69]. Therefore, our study finding of the decreased percentage of CD40+, CD192+, and CD14+CD16++ monocytes probably indicates the beneficial effects of ocrelizumab therapy, which causes decreased entrance of monocytes into the CNS and decreased T and B cell activation compared to untreated PPMS subjects. In the present study, all PPMS subjects had decreased percentages of classical monocytes positive for CD192, but the surface expression of CD192 (MFI), both in untreated and treated PPMS subjects, was increased. The original studies of anti-CD20 antibodies in patients with multiple sclerosis assumed that depletion of CD20-expressing B cells may reduce elevated cerebrospinal fluid immunoglobulins [70]. Furthermore, small subsets of CD4+ and CD8+ T cells that also express CD20 can be depleted with anti-CD20 [71,72], indicating that anti-CD20 treatment directly removes pathogenic T CD20+. The presence of abnormally proinflammatory B cells in, which serve as antigen-presenting cells, in untreated MS patients was found to activate potentially pathogenic T cells and myeloid cells [73]. In addition, CD16+ nonclassical and intermediate monocytes can serve as antigen-presenting cells, which activate cytotoxic CD8+ T cells and destroy myelin [74]. Wong et al. [75] found the highest MHC class I (responsible for antigen presentation) expression in intermediate monocytes, and Zawada et al. [76] found their highest expression in nonclassical monocytes. Knowing these pathogenesis steps, we can assume the lower percentages of CD40+ and CD192+ nonclassical monocytes in treated patients in our study to be novel markers of the beneficial effect of anti-CD20 therapy (Figure 5).

The CD16+ monocyte subpopulations preferentially become migratory dendritic cells [77]. These CD16+ monocyte-derived cells may promote their survival as well as the survival and differentiation of CD16- cells derived from classical monocytes. This means that some nonclassical monocyte subpopulations are superior and direct the destiny of major classical monocyte subpopulations. Recently, it was shown that the removal of T and B cells by anti-CD20 therapy alters their interactions in vivo [78]. Considering that CD40+ and CD192+ nonclassical monocytes lack the CD20 antigen, their decreased percentages in ocrelizumab-treated patients are the indirect results of altered T and B cell interactions.

Tregs express several surface markers and their persistent expression is crucial for maintaining the suppressive functionality of differentiated Treg cells (FOXP3) and effective modulation of the immune responses of CTLA-4. Their increased percentages can possibly contribute to inhibiting the abnormal immune response in PPMS. All PPMS subjects had significant increases in their percentages of CD4+CD25+FOXP3+, with greater significance levels in untreated PPMS subjects. Untreated PPMS subjects had a significant difference in CD4+CD25+highFOXP3+ compared to HCs, but treated PPMS subjects did not. This may prove that ocrelizumab suppresses autoimmune response, which is reflected in lower numbers of Tregs in ocrelizumab-treated PPMS subjects. Knowing that monocyte CD40 leads to T and B cell activation and CNS inflammation, and that monocyte CD192 enables monocytes to cross the blood–CNS barrier, decreased percentages of CD14+CD16++ monocytes may indicate a beneficial effect of ocrelizumab therapy. Lastly, our study has several limitations to mention. First, it comprises a relatively small number of PPMS subjects who could be enrolled in the study from the University Hospital of Split. Second, the possible effects of differences in MS disease duration between ocrelizumab treated and untreated PPMS subjects were not investigated due to the relatively small sample size.

It is recommended that further studies include PPMS subjects with higher EDSS scores, control for the duration of the MS disease between ocrelizumab-treated and untreated PPMS subjects, and balance more appropriately the age of the healthy control subjects. Longitudinal follow-up is also recommended to gain more insights into the clinical relevance of the expression of CD40 and CD192 in monocytes and Treg lymphocytes in PPMS subjects.

Acknowledgments

We would like to thank the nurses Ljubica Trogrlić and Matea Eterović-Budin from the Department of Neurology (University Hospital of Split) for their caring help with the preparation of peripheral blood samples. Most importantly, we thank our participants, people with multiple sclerosis, and healthy subjects who voluntarily participated in the study.

Author Contributions

Conceptualization, N.I., S.P. and M.R.V.; methodology, N.I., N.R.M., S.P., A.M. and M.B.Š.; software, N.R.M. and J.Š.; formal analysis, N.I. and N.R.M.; investigation, N.I., N.R.M., M.B.Š., K.D. and S.P.; resources, K.D. and S.P.; data curation, S.P. and K.D.; writing—original draft preparation, N.I., N.R.M., M.R.V. and M.B.Š.; writing—review and editing, A.M., M.R.V., M.B.Š., J.Š. and N.I.; visualization, N.R.M. and J.Š; supervision, M.R.V. and A.M. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the institutional ethical committee board of the University of Split, School of Medicine (Class: 003-08/21-03/0003, No: 2181-198-03-04-21-0039, approved 10 March 2020, and last annex Class: 003-08/23-03/0015, No: 2181-198-03-04-23-0075, approved 27 September 2023) and the University Hospital of Split (Class: 500-03/20-01/06, No: 2181-147-01/06/M.S., approved 27 January 2020, and last annex Class: 500-03/20-01/06, No: 2181-147-01-06/Lj.Z.-23-04, approved 20 September 2023).

Informed Consent Statement

Written informed consent has been obtained from the patient(s) to publish this paper.

Data Availability Statement

Further information regarding the resources and data availability should be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Figure 1 MFI of FOXP3 on CD4+CD25+high (A) and CD4+CD25+ (B) in HCs and PPMS subjects (p < 0.05; p < 0.01).

Figure 2 Representative gates for monocyte (A) and the monocyte subpopulations nonclassical (CD14+CD16++), intermediate (CD14++CD16+), and classical (CD14++CD16−) (B).

Figure 3 Representative dot plots for unstained sample (A), control total monocyte dot plots stained for CD14 (B), and only CD192 (C).

Figure 4 Percentages of CD40+ and CD192+ nonclassical monocytes in treated and untreated subjects. p < 0.01; p < 0.05.

Figure 5 The role of nonclassical monocytes in mediating demyelination.

biomedicines-12-00464-t001_Table 1 Table 1 Demographic and disease related characteristics of ocrelizumab treated and untreated PPMS subjects and HCs.

Parameter	All
PPMS (N = 28)	Treated
PPMS (N = 15)	Untreated PPMS (N = 13)	HCs (N = 10)	
Mean ± SD	
Age (years)	54.57 ± 8.71	53 ± 7.47	56.3 ± 9.97	37 ± 13.90	
EDSS	4.94 ± 1.54	4.8 ± 1.53	5.11 ± 1.6	/	
Disease duration (years)	10.74 ± 7.58	6.86 ± 5.39	15.58 ± 7.26	/	
Female/Male (N)	21/7	13/2	8/5	6/4	
Basic parametric data are presented as mean ± standard deviation. Categorical data are presented as numbers. Abbreviations: PPMS—primary progressive MS; HCs—healthy controls; N—number of subjects.

biomedicines-12-00464-t002_Table 2 Table 2 Lymphocyte marker expression in PPMS subjects and HCs.

		% of CD4+
CD25+high	MFI of CD4+
CD25+high	% of CD4+ CD25+high
FOXP3+	MFI of CD4+ CD25+high
FOXP3+	% of CD4+ CD25+	MFI of CD4+CD25+	% of CD4+
CD25+
FOXP3+	MFI of
CD4+
CD25+
FOXP3+	
Treated PPMS (N = 15)	M	3.02	3720.74	10.57	1798.26	5.502	36,098.34	21.89	1866.49	
SD	0.66	399.85	3.06	433.07	1.28	3422.33	5.41	474.53	
HCs (N = 10)	M	2.56	3550.99	8.63	1417.0.3	4.54	34,907.46	15.48	1415.77	
SD	0.65	154.51	1.28	233.17	0.91	2195.62	2.63	209.94	
Untreated PPMS (N = 13)	M	3.7	3679.51	11.06	1687.15	6.26	35,148.44	21.03	1744.54	
SD	1.08	215.02	2.68	258.27	1.76	3060.79	3.91	232.4	
All PPMS (N = 28)	M	3.33	3701.6	10.76	1746.68	5.85	35,657.31	21.49	1809.87	
SD	0.93	322.32	2.89	360.6711	1.54	3235.67	4.71	380.26	
All PPMS vs. HCs	t	2.4	1.14	2.22	2.69	2.47	0.67	3.8	3	
df	37	37	37	37	37	37	37	37	
p	0.02 *	0.16	0.03 *	0.01 *	0.01 *	0.05	0.0005 ***	0.003 **	
Treated PPMS vs. HCs	t	1.7	1.27	1.88	2.55	1.99	0.97	3.46	2.81	
df	24	24	24	24	24	24	24	24	
p	0.1	0.21	0.07	0.01 *	0.058	0.34	0.002 **	0.009 **	
Untreated PPMS vs. HCs	t	2.9	1.56	2.62	2.63	2.76	0.21	3.84	3.5	
df	22	22	22	22	22	22	22	22	
p	0.008 **	0.12	0.01*	0.01 *	0.01 *	0.83	0.0009 ***	0.002 **	
Treated PPMS vs. Untreated PPMS	t	2	0.33	0.43	0.8	1.32	0.76	0.47	0.84	
df	27	27	27	27	27	27	27	27	
p	0.053	0.74	0.66	0.42	0.19	0.44	0.63	0.4	
Abbreviations: PPMS—primary progressive multiple sclerosis; HCs—healthy controls; %—percentage; MFI—median fluorescence intensity; M—arithmetic mean; SD—standard deviation; df—degree of freedom; t—t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.

biomedicines-12-00464-t003_Table 3 Table 3 CTLA-4 marker expression in CD4+CD25- lymphocytes and Tregs in PPMS subjects and HCs.

		% of CD4+CD25−CTLA-4+	MFI of CTLA-4+ in CD4+CD25−	% of CD4+ CTLA-4+	MFI of CD4+ CTLA-4+	% of CD4+CD25+ FOXP3+ CTLA-4+	MFI of CD4+CD25+ FOXP3+ CTLA-4+	
Treated PPMS (N = 15)	M	39.96	1327.11	15.29	2742.4	34.01	2378.26	
SD	9.59	196.92	4.34	144.93	7.84	294.41	
HCs (N = 10)	M	36.61	1179.32	12.65	2711.42	25.57	2291.86	
SD	7.01	60.62	3.51	194.87	3.89	294.41	
Untreated PPMS (N = 13)	M	42.16	1278.63	14.86	2652.08	30.41	2372.1	
SD	5.67	151.23	3.72	124.01	4.99	259	
All PPMS (N = 28)	M	40.98	1308.14	15.09	2700.47	32.34	2375.4	
SD	7.95	178.37	4.00	140.82	6.08	273.44	
All PPMS vs. HCs	t	1.53	2.1	1.7	0.19	2.96	0.85	
df	37	31	37	37	37	36	
p	0.13	0.04 *	0.09	0.85	0.005 **	0.4	
Treated PPMS vs. HCs	t	0.94	2.17	1.59	0.45	3.14	0.78	
df	24	22	24	22	24	23	
p	0.35	0.04 *	0.12	0.93	0.004 **	0.44	
Untreated PPMS vs. HCs	t	2.09	1.82	1.44	0.89	2.53	0.79	
df	22	17	22	22	22	21	
p	0.04 *	0.08	0.16	0.38	0.01 *	0.43	
Treated PPMS vs. Untreated PPMS	t	0.72	0.62	0.27	1.75	1.42	0.05	
df	27	22	27	27	27	27	
p	0.47	0.53	0.78	0.09	0.16	0.95	
Abbreviations: PPMS—primary progressive multiple sclerosis; HCs—healthy controls; %—percentage; MFI—median fluorescence intensity; M—arithmetic mean; SD—standard deviation; df—degree of freedom; t—t-test. * p < 0.05; ** p < 0.01.

biomedicines-12-00464-t004_Table 4 Table 4 The differences in monocyte marker expression in PPMS subjects and HC subjects.

		% of CD40+
CD14++CD16−	MFI of CD40 in
CD14++CD16−	% of CD192+ CD14++CD16−	MFI of CD192+ in CD14++CD16−	% of CD14++
CD16+	% of CD40+ in CD14++CD16+	MFI of CD40+ in CD14++CD16+	% of CD40+ in CD14+CD16++	% of CD192+ in CD14+CD16++	
Treated PPMS (N = 15)	M	60.48	4200.943	83.92	101,066.2	7.37	79.59	9922.6	61.09	62.82	
SD	23.26	1398.083	9.665	8739.41	4.59	16.34	3149.26	11.67	15.3	
HC
(N = 10)	M	49.82	3442.95	97.77	81,837.85	3.53	83.274	8774.08	65.4	70.3	
SD	19.96	796.503	1.53	8242.14	2.37	6.36	2163.78	20.32	20.95	
Untreated PPMS (N = 13)	M	52.142	3596.253	84.1	95,454.87	6.11	83.02	10,381.84	75.69	76.19	
SD	19.20	751.187	13.04	10,285.6	4.6	18.16	4155.25	13.61	13.13	
All PPMS (N = 28)	M	56.61	3920.19	84.003	98,461	6.79	81.18	10,135.82	67.58	68.76	
SD	21.5	1165.84	11.13	9733.66	6.75	16.97	3586.68	14.36	15.65	
All PPMS vs. HCs	t	0.87	1.19	3.9	4.8	2.11	0.37	1.12	0.36	0.24	
df	37	37	37	37	37	37	37	36	36	
p	0.38	0.24	0.0004 **	0.00002 ***	0.041 *	0.7	0.26	0.7	0.81	
Treated PPMS vs. HCs	t	1.19	1.5	4.46	5.5	2.42	0.67	1	0.67	1.03	
df	24	24	24	24	24	24	24	24	24	
p	0.24	0.13	0.0001 ***	0.00001 ***	0.02 *	0.5	0.32	0.5	0.31	
Untreated PPMS vs. HCs	t	0.28	0.47	3.28	3.4	−1.56	0.04	1.1	1.41	0.8	
df	22	22	22	22	22	22	22	21	21	
p	0.77	0.64	0.003*	0.002**	0.13	0.96	0.27	0.17	0.43	
Treated PPMS vs. Untreated PPMS	t	1.02	1.3	0.04	1.5	0.71	0.52	0.33	3	2.39	
df	27	27	27	27	27	27	27	36	26	
p	0.31	0.17	0.96	0.13	0.48	0.6	0.74	0.006 ***	0.02 *	
Abbreviations: PPMS—primary progressive multiple sclerosis; HCs—healthy controls; %—percentage; MFI—median fluorescence intensity; M—arithmetic mean; SD—standard deviation; df—degree of freedom; t—t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Axisa P.P. Hafler D.A. Multiple sclerosis: Genetics, biomarkers, treatments Curr. Opin. Neurol. 2016 29 345 353 10.1097/WCO.0000000000000319 27058221
2. Hafler D.A. Multiple sclerosis J. Clin. Investig. 2004 113 788 794 10.1172/JCI21357 15067307
3. Klineova S. Lublin F.D. Clinical Course of Multiple Sclerosis Cold Spring Harb. Perspect. Med. 2018 8 a028928 10.1101/cshperspect.a028928 29358317
4. McGinley M.P. Goldschmidt C.H. Rae-Grant A.D. Diagnosis and Treatment of Multiple Sclerosis: A Review JAMA 2021 325 765 779 10.1001/jama.2020.26858 33620411
5. Lassmann H. Brück W. Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy Trends Mol. Med. 2001 7 115 121 10.1016/S1471-4914(00)01909-2 11286782
6. Pitteri M. Romualdi C. Magliozzi R. Monaco S. Calabrese M. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study Mult. Scler. 2017 23 848 854 10.1177/1352458516665496 27527906
7. Goverman J. Autoimmune T cell responses in the central nervous system Nat. Rev. Immunol. 2009 9 393 407 10.1038/nri2550 19444307
8. Dendrou C.A. Fugger L. Friese M.A. Immunopathology of multiple sclerosis Nat. Rev. Immunol. 2015 15 545 558 10.1038/nri3871 26250739
9. van Langelaar J. Rijvers L. Smolders J. van Luijn M.M. B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers Front. Immunol. 2020 11 760 10.3389/fimmu.2020.00760 32457742
10. Monti P. Heninger A.K. Bonifacio E. Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus Curr. Diabetes Rep. 2009 9 113 118 10.1007/s11892-009-0020-y
11. Iijima W. Ohtani H. Nakayama T. Sugawara Y. Sato E. Nagura H. Yoshie O. Sasano T. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: A potential self-recruiting mechanism Am. J. Pathol. 2003 163 261 268 10.1016/S0002-9440(10)63649-8 12819030
12. Cao Y. Amezquita R.A. Kleinstein S.H. Stathopoulos P. Nowak R.J. O’Connor K.C. Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production J. Immunol. 2016 196 2075 2084 10.4049/jimmunol.1501339 26826242
13. Diani M. Altomare G. Reali E. T cell responses in psoriasis and psoriatic arthritis Autoimmun. Rev. 2015 14 286 292 10.1016/j.autrev.2014.11.012 25445403
14. Schreurs O. Karatsaidis A. Schenck K. Phenotypically non-suppressive cells predominate among FOXP3-positive cells in oral lichen planus J. Oral. Pathol. Med. 2016 45 766 773 10.1111/jop.12447 27084447
15. Xufré C. Costa M. Roura-Mir C. Codina-Busqueta E. Usero L. Pizarro E. Obiols G. Jaraquemada D. Martí M. Low frequency of GITR+ T cells in ex vivo and in vitro expanded Treg cells from type 1 diabetic patients Int. Immunol. 2013 25 563 574 10.1093/intimm/dxt020 23929911
16. Richetta A.G. Mattozzi C. Salvi M. Giancristoforo S. D’epiro S. Milana B. Carboni V. Zampetti M. Calvieri S. Morrone S. CD4+CD25+ T-regulatory cells in psoriasis. Correlation between their numbers and biologics-induced clinical improvement Eur. J. Dermatol. 2011 21 344 348 10.1684/ejd.2011.1362 21680285
17. Su Q.Y. Zhang S.X. Yang L. Luo J. Li X.F. Zhang J.Q. Zhang Y. Liu J.Q. Shi L. Peripheral Treg Levels and Transforming Growth Factor-β (TGFβ) in Patients with Psoriatic Arthritis: A Systematic Review Meta-Analysis Adv. Ther. 2023 40 102 116 10.1007/s12325-022-02337-5 36287319
18. Thiruppathi M. Rowin J. Li Jiang Q. Sheng J.R. Prabhakar B.S. Meriggioli M.N. Functional defect in regulatory T cells in myasthenia gravis Ann. N. Y. Acad. Sci. 2012 1274 68 76 10.1111/j.1749-6632.2012.06840.x 23252899
19. Kohler S. Keil T.O.P. Hoffmann S. Swierzy M. Ismail M. Rückert J.C. Alexander T. Meisel A. CD4+ FOXP3+ T regulatory cell subsets in myasthenia gravis patients Clin. Immunol. 2017 179 40 46 10.1016/j.clim.2017.03.003 28286113
20. Chi L.J. Wang H.B. Zhang Y. Wang W.Z. Abnormality of circulating CD4+ CD25+ regulatory T cell in patients with Guillain-Barré syndrome J. Neuroimmunol. 2007 192 206 214 10.1016/j.jneuroim.2007.09.034 17997492
21. Tapia-Maltos M.A. Treviño-Frenk I. García-González H.B. Rosetti M. Barriga-Maldonado V. Morales-Ramírez F. López-Hernández D.C. Rosetti F. Crispín J.C. Identification of regulatory T cell molecules associated with severity of multiple sclerosis Mult. Scler. 2021 27 1695 1705 10.1177/1352458520977045 33300840
22. Dalla Libera D. Di Mitri D. Bergami A. Centonze D. Gasperini C. Grasso M.G. Galgani S. Martinelli V. Comi G. Avolio C. T regulatory cells are markers of disease activity in multiple sclerosis patients PLoS ONE 2011 6 e21386 10.1371/journal.pone.0021386 21731726
23. Bjerg L. Brosbøl-Ravnborg A. Tørring C. Dige A. Bundgaard B. Petersen T. Höllsberg P. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients J. Neuroimmunol. 2012 249 76 82 10.1016/j.jneuroim.2012.04.012 22608884
24. Viglietta V. Baecher-Allan C. Weiner H.L. Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis J. Exp. Med. 2004 199 971 979 10.1084/jem.20031579 15067033
25. Venken K. Hellings N. Thewissen M. Somers V. Hensen K. Rummens J.L. Medaer R. Hupperts R. Stinissen P. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level Immunology 2008 123 79 89 10.1111/j.1365-2567.2007.02690.x 17897326
26. Haas J. Hug A. Viehöver A. Fritzsching B. Falk C.S. Filser A. Vetter T. Milkova L. Korporal M. Fritz B. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis Eur. J. Immunol. 2005 35 3343 3352 10.1002/eji.200526065 16206232
27. Li R. Li H. Yang X. Hu H. Liu P. Liu H. Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis Front. Immunol. 2022 13 970508 10.3389/fimmu.2022.970508 36177043
28. Colamatteo A. Carbone F. Bruzzaniti S. Galgani M. Fusco C. Maniscalco G.T. Di Rella F. de Candia P. De Rosa V. Molecular Mechanisms Controlling FOXp3 Expression in Health and Autoimmunity: From Epigenetic to Post-translational Regulation Front. Immunol. 2020 10 3136 10.3389/fimmu.2019.03136 32117202
29. Eggenhuizen P.J. Ng B.H. Ooi J.D. Treg Enhancing Therapies to Treat Autoimmune Diseases Int. J. Mol. Sci. 2020 21 7015 10.3390/ijms21197015 32977677
30. Nie J. Li Y.Y. Zheng S.G. Tsun A. Li B. FOXP3(+) Treg Cells and Gender Bias in Autoimmune Diseases Front. Immunol. 2015 6 493 10.3389/fimmu.2015.00493 26441996
31. Danikowski K.M. Jayaraman S. Prabhakar B.S. Regulatory T cells in multiple sclerosis and myasthenia gravis J. Neuroinflamm. 2017 14 117 10.1186/s12974-017-0892-8 28599652
32. Tekguc M. Wing J.B. Osaki M. Long J. Sakaguchi S. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells Proc. Natl. Acad. Sci. USA 2021 118 e2023739118 10.1073/pnas.2023739118 34301886
33. Calahorra L. Camacho-Toledano C. Serrano-Regal M.P. Ortega M.C. Clemente D. Regulatory Cells in Multiple Sclerosis: From Blood to Brain Biomedicines 2022 10 335 10.3390/biomedicines10020335 35203544
34. Carstensen M. Christensen T. Stilund M. Møller H.J. Petersen E.L. Petersen T. Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis Immunol. Cell Biol. 2020 98 549 562 10.1111/imcb.12337 32253768
35. Waschbisch A. Schröder S. Schraudner D. Sammet L. Weksler B. Melms A. Pfeifenbring S. Stadelmann C. Schwab S. Linker R.A. Pivotal Role for CD16+ Monocytes in Immune Surveillance of the Central Nervous System J. Immunol. 2016 196 1558 1567 10.4049/jimmunol.1501960 26746191
36. Gjelstrup M.C. Stilund M. Petersen T. Møller H.J. Petersen E.L. Christensen T. Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis Immunol. Cell Biol. 2018 96 160 174 10.1111/imcb.1025 29363161
37. Dargahi N. Katsara M. Tselios T. Androutsou M.E. de Courten M. Matsoukas J. Apostolopoulos V. Multiple Sclerosis: Immunopathology and Treatment Update Brain Sci. 2017 7 78 10.3390/brainsci7070078 28686222
38. Hauser S.L. Cree B.A.C. Treatment of Multiple Sclerosis: A Review Am. J. Med. 2020 133 1380 1390.e2 10.1016/j.amjmed.2020.05.049 32682869
39. Kimura K. Regulatory T cells in multiple sclerosis Clin. Exp. Neuroimmunol. 2020 11 148 155 10.1111/cen3.12591
40. Williams L.M. Rudensky A.Y. Maintenance of the FOXp3-dependent developmental program in mature regulatory T cells requires continued expression of FOXp3 Nat. Immunol. 2007 8 277 284 10.1038/ni1437 17220892
41. Ben-Skowronek I. IPEX Syndrome: Genetics and Treatment Options Genes 2021 12 323 10.3390/genes12030323 33668198
42. Leon J. Chowdhary K. Zhang W. Ramirez R.N. André I. Hur S. Mathis D. Benoist C. Mutations from patients with IPEX ported to mice reveal different patterns of FOXP3 and Treg dysfunction Cell Rep. 2023 42 113018 10.1016/j.celrep.2023.113018 37605532
43. Li Y.F. Zhang S.X. Ma X.W. Xue Y.L. Gao C. Li X.Y. Xu A.D. The proportion of peripheral regulatory T cells in patients with Multiple Sclerosis: A meta-analysis Mult. Scler. Relat. Disord. 2019 28 75 80 10.1016/j.msard.2018.12.019 30572285
44. González-Oria M.C. Márquez-Coello M. Girón-Ortega J.A. Argente J. Moya M. Girón-González J.A. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects J. Neuroimmune Pharmacol. Off. J. Soc. Neuroimmune Pharmacol. 2019 14 413 422 10.1007/s11481-018-09832-z
45. Kouchaki E. Salehi M. Reza Sharif M. Nikoueinejad H. Akbari H. Numerical status of CD4+CD25+FOXP3+ and CD8+CD28− regulatory T cells in multiple sclerosis Iran. J. Basic. Med. Sci. 2014 17 250 255 10.22038/IJBMS.2014.2582 24904717
46. Howlett-Prieto Q. Feng X. Kramer J.F. Kramer K.J. Houston T.W. Reder A.T. Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis Mult. Scler. 2021 27 2170 2179 10.1177/13524585211003301 33783270
47. Seidel J.A. Otsuka A. Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations Front. Oncol. 2018 8 86 10.3389/fonc.2018.00086 29644214
48. Chan D.V. Gibson H.M. Aufiero B.M. Wilson A.J. Hafner M.S. Mi Q.S. Wong H.K. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation Genes Immun. 2014 15 25 32 10.1038/gene.2013.57 24173147
49. Yi J.S. Cox M.A. Zajac A.J. T-cell exhaustion: Characteristics, causes and conversion Immunology 2010 129 474 481 10.1111/j.1365-2567.2010.03255.x 20201977
50. Sellebjerg F. Krakauer M. Khademi M. Olsson T. Sørensen P.S. FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+ CD25high T cells in multiple sclerosis Clin. Exp. Immunol. 2012 170 149 155 10.1111/j.1365-2249.2012.04654.x 23039885
51. Medina S. Sainz de la Maza S. Villarrubia N. Álvarez-Lafuente R. Costa-Frossard L. Arroyo R. Monreal E. Tejeda-Velarde A. Rodríguez-Martín E. Roldán E. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients Ann. Clin. Transl. Neurol. 2019 6 355 363 10.1002/acn3.711 30847367
52. Rabe H. Lundell A.C. Andersson K. Adlerberth I. Wold A.E. Rudin A. Higher proportions of circulating FOXP3+ and CTLA-4+ regulatory T cells are associated with lower fractions of memory CD4+ T cells in infants J. Leukoc. Biol. 2011 90 1133 1140 10.1189/jlb.0511244 21934066
53. Mohammadzadeh A. Rad I.A. Ahmadi-Salmasi B. CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients J. Neuroimmunol. 2018 323 105 108 10.1016/j.jneuroim.2018.08.004 30196822
54. Wang H. Wang K. Zhong X. Dai Y. Wu A. Li Y. Hu X. Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse J. Neuroimmunol. 2012 243 52 55 10.1016/j.jneuroim.2011.11.010 22177277
55. Derakhshani A. Asadzadeh Z. Safarpour H. Leone P. Shadbad M.A. Heydari A. Baradaran B. Racanelli V. Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs J. Pers. Med. 2021 11 721 10.3390/jpm11080721 34442365
56. Mena E. Rohowsky-Kochan C. Expression of costimulatory molecules on peripheral blood mononuclear cells in multiple sclerosis Acta Neurol. Scand. 1999 100 92 96 10.1111/j.1600-0404.1999.tb01044.x 10442449
57. Lavon I. Heli C. Brill L. Charbit H. Vaknin-Dembinsky A. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis Front. Immunol. 2019 10 835 10.3389/fimmu.2019.00835 31134049
58. Oliveira E.M. Bar-Or A. Waliszewska A.I. Cai G. Anderson D.E. Krieger J.I. Hafler D.A. CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls J. Autoimmun. 2003 20 71 81 10.1016/S0896-8411(02)00106-3 12604314
59. Kosmaczewska A. Bilinska M. Ciszak L. Noga L. Pawlak E. Szteblich A. Podemski R. Frydecka I. Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS) J. Neuroimmunol. 2007 189 137 146 10.1016/j.jneuroim.2007.06.021 17669511
60. Bar-Or A. The immunology of multiple sclerosis Semin. Neurol. 2008 28 29 45 10.1055/s-2007-1019124 18256985
61. Steinbach K. Piedavent M. Bauer S. Neumann J.T. Friese M.A. Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs J. Immunol. 2013 191 4531 4539 10.4049/jimmunol.1202613 24062488
62. Ajami B. Bennett J.L. Krieger C. McNagny K.M. Rossi F.M.V. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool Nat. Neurosci. 2011 14 1142 1149 10.1038/nn.2887 21804537
63. Mitsdoerffer M. Schreiner B. Kieseier B.C. Neuhaus O. Dichgans J. Hartung H.P. Weller M. Wiendl H. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-β in vitro and in vivo: Rationale for the therapy of multiple sclerosis J. Neuroimunol. 2005 159 155 164 10.1016/j.jneuroim.2004.09.016 15652415
64. Ziegler-Heitbrock L. The CD14þ CD16þ blood monocytes: Their role in infection and inflammation J. Leukoc. Biol. 2007 81 584592 10.1189/jlb.0806510 17135573
65. Chuluundorj D. Harding S.A. Abernethy D. La Flamme A.C. Expansion and preferential activation of the CD14+CD16+ monocyte subset during multiple sclerosis Immunol. Cell Biol. 2014 92 509 517 10.1038/icb.2014.15 24638064
66. Haschka D. Tymoszuk P. Bsteh G. Petzer V. Berek K. Theurl I. Berger T. Weiss G. Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis Front. Immunol. 2020 29 594 10.3389/fimmu.2020.00594
67. Mukherjee R. Kanti Barman P. Kumar Thatoi P. Tripathy R. Kumar Das B. Ravindran B. Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous Sci. Rep. 2015 5 13886 10.1038/srep13886 26358827
68. Paré A. Mailhot B. Lévesque S.A. Juzwik C. Ignatius Arokia Doss P.M. Lécuyer M.A. Prat A. Rangachari M. Fournier A. Lacroix S. IL-1β enables CNS access to CCR2hi monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells Proc. Natl. Acad. Sci. USA 2018 115 1194 1203 10.1073/pnas.1714948115 29358392
69. Chitnis T. Khoury S.J. Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis J. Allergy Clin. Immunol. 2003 112 837 849 10.1016/j.jaci.2003.08.025 14610467
70. Breij E.C. Brink B.P. Veerhuis R. Van den Berg C. Vloet R. Yan R. Dijkstra C.D. Van der Valk P. Bö L. Homogeneity of active demyelinating lesions in established multiple sclerosis Ann. Neurol. 2008 63 16 25 10.1002/ana.21311 18232012
71. Von Essen M.R. Ammitzbøll C. Hansen R.H. Petersen E.R.S. McWilliam O. Marquart H.V. Damm P. Sellebjerg F. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis Brain 2019 142 120 132 10.1093/brain/awy301 30561509
72. Sabatino J.J. Jr. Wilson M.R. Calabresi P.A. Hauser S.L. Schneck J.P. Zamvil S.S. Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis Proc. Natl. Acad. Sci. USA 2019 116 25800 25807 10.1073/pnas.1915309116 31748274
73. Bar-Or A. Fawaz L. Fan B. Darlington P.J. Rieger A. Ghorayeb C. Calabresi P.A. Waubant E. Hauser S.L. Zhang J. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol. 2010 67 452 461 10.1002/ana.21939 20437580
74. Wong K.L. Yeap W.H. Tai J.J. Ong S.M. Dang T.M. Wong S.C. The three human monocyte subsets: Implications for health and disease Immunol. Res. 2012 53 41 57 10.1007/s12026-012-8297-3 22430559
75. Wong K.L. Tai J.J. Wong W.C. Han H. Sem X. Yeap W.H. Kourilsky P. Wong S.C. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets Blood 2011 118 e16 e31 10.1182/blood-2010-12-326355 21653326
76. Zawada A.M. Rogacev K.S. Rotter B. Winter P. Marell R.R. Fliser D. Heine G.H. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset Blood 2011 118 e50 e61 10.1182/blood-2011-01-326827 21803849
77. Randolph G.J. Sanchez-Schmitz G. Liebman R.M. Schäkel K. The CD16+ (FcγRIII+) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting J. Exp. Med. 2002 196 517 527 Erratum in: J. Exp. Med. 2002, 196, 869 10.1084/jem.20011608 12186843
78. Shinoda K. Li R. Rezk A. Mexhitaj I. Patterson K.R. Kakara M. Zuroff L. Bennett J.L. von Büdingen H.C. Carruthers R. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity Proc. Natl. Acad. Sci. USA 2023 120 e2207291120 10.1073/pnas.2207291120 36634138
